Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study

  • Chang, Hye Jin (Health Promotion Center, Seoul National University Bundang Hospital) ;
  • Lee, Jung Ryeol (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Jee, Byung Chul (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Suh, Chang Suk (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Lee, Won Don (Maria Infertility Hospital) ;
  • Kim, Seok Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
  • Received : 2013.04.11
  • Accepted : 2013.05.15
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate outcomes of stimulated IVF cycles in which GnRH antagonist was omitted on the ovulation triggering day. Methods: A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B). The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles). The maturity of oocytes, fertilization rate, embryo quality, and implantation and clinical pregnancy rates were evaluated. Results: The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in group B than group A ($2.5{\pm}0.9$ vs. $3.2{\pm}0.8$ ampoules, p<0.05). There was no premature luteinization in any of the subjects. The proportion of mature oocytes and fertilization rate were not significantly different in group B than group A (70.7% vs. 66.7%; 71.1% vs. 66.4%, respectively). There were no significant differences in the implantation or clinical pregnancy rates. Conclusion: Our prospective randomized study suggested that cessation of GnRH antagonist on the hCG administration day during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising its effects on pregnancy rates.

Keywords

References

  1. Cetel NS, Rivier J, Vale W, Yen SS. The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin- releasing hormone. J Clin Endocrinol Metab 1983; 57:62-5. https://doi.org/10.1210/jcem-57-1-62
  2. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin- releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917-22. https://doi.org/10.1016/S0015-0282(97)81407-0
  3. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788-91.
  4. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874-85. https://doi.org/10.1093/humrep/17.4.874
  5. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;(3):CD001750.
  6. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and metaanalysis. Hum Reprod Update 2006;12:651-71. https://doi.org/10.1093/humupd/dml038
  7. Hsueh AJ, Adashi EY, Jones PB, Welsh TH Jr. Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocr Rev 1984;5:76-127. https://doi.org/10.1210/edrv-5-1-76
  8. Zeleznik AJ, Hillier SG. The role of gonadotropins in the selection of the preovulatory follicle. Clin Obstet Gynecol 1984;27:927-40. https://doi.org/10.1097/00003081-198412000-00014
  9. Chang HJ, Lee JR, Jee BC, Suh CS, Kim SH. Cessation of gonadotropin- releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocol. J Korean Med Sci 2009;24:262-8. https://doi.org/10.3346/jkms.2009.24.2.262
  10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  11. Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988;541:259-74. https://doi.org/10.1111/j.1749-6632.1988.tb22263.x
  12. Allegra A, Marino A, Coffaro F, Scaglione P, Sammartano F, Rizza G, et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod 2007;22:101-8. https://doi.org/10.1093/humrep/dem1065
  13. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333-40. https://doi.org/10.1093/humupd/dml001
  14. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;(4):CD001750.
  15. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003;18:2698-703. https://doi.org/10.1093/humrep/deg516
  16. Fanchin R, Castelo Branco A, Kadoch IJ, Hosny G, Bagirova M, Frydman R. Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation. Fertil Steril 2004;81:1554-9. https://doi.org/10.1016/j.fertnstert.2003.11.037
  17. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod 2006;21:352-7.
  18. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003;88:5632-7. https://doi.org/10.1210/jc.2003-030805
  19. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin- releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003;79:873-80. https://doi.org/10.1016/S0015-0282(02)04920-8
  20. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecol Endocrinol 2005;20:161-9. https://doi.org/10.1080/09513590400027232
  21. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526-31. https://doi.org/10.1093/humrep/15.3.526
  22. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-20. https://doi.org/10.1016/S0015-0282(99)00524-5
  23. Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P. Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reprod Biomed Online 2003;7:185-9. https://doi.org/10.1016/S1472-6483(10)61749-X
  24. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12:159-68. https://doi.org/10.1093/humupd/dmi045
  25. Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am J Obstet Gynecol 1995;172:1518-25. https://doi.org/10.1016/0002-9378(95)90490-5
  26. Cota AM, Oliveira JB, Petersen CG, Mauri AL, Massaro FC, Silva LF, et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reprod Biol Endocrinol 2012;10: 33. https://doi.org/10.1186/1477-7827-10-33
  27. Kyrou D, Verpoest W, Staessen C, De Vos A, Haentjens P, Liebaers I, et al. No relationship between the type of pituitary suppression for IVF and chromosomal abnormality rates of blastomeres: an observational study. Fertil Steril 2011;95:563-7. https://doi.org/10.1016/j.fertnstert.2010.05.020
  28. Munoz M, Cruz M, Humaidan P, Garrido N, Perez-Cano I, Meseguer M. The type of GnRH analogue used during controlled ovarian stimulation influences early embryo developmental kinetics: a time-lapse study. Eur J Obstet Gynecol Reprod Biol 2013;168: 167-72. https://doi.org/10.1016/j.ejogrb.2012.12.038
  29. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000;15:1211-6. https://doi.org/10.1093/humrep/15.6.1211
  30. Gordon K. Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity. Ann N Y Acad Sci 2001;943:49-54. https://doi.org/10.1111/j.1749-6632.2001.tb03789.x
  31. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dosefinding study group. Hum Reprod 1998;13:3023-31. https://doi.org/10.1093/humrep/13.11.3023
  32. Seelig AS, Al-Hasani S, Katalinic A, Schopper B, Sturm R, Diedrich K, et al. Comparison of cryopreservation outcome with gonadotropin- releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 2002;77:472-5. https://doi.org/10.1016/S0015-0282(01)03008-4
  33. Taylor HS, Daftary GS, Selam B. Endometrial HOXA10 expression after controlled ovarian hyperstimulation with recombinant follicle- stimulating hormone. Fertil Steril 2003;80 Suppl 2:839-43. https://doi.org/10.1016/S0015-0282(03)00985-3
  34. Sirayapiwat P, Triratanachat S, Tantbirojn P, Ruangvejvorachai P, Suwajanakorn S. HOXA10 protein expression in the endometrium of normally menstruating women after receiving GnRH antagonist. Eur J Obstet Gynecol Reprod Biol 2013 Mar 28 [Epub]. http://dx.doi.org/10.1016/j.ejogrb.2013.03.006.
  35. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertil Steril 2008;89:1234-9. https://doi.org/10.1016/j.fertnstert.2007.04.060

Cited by

  1. Cost-effectiveness of GnRH antagonist implementation on hCG injection day vol.16, pp.1, 2013, https://doi.org/10.4274/tjod.galenos.2019.56255
  2. GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve vol.12, pp.None, 2021, https://doi.org/10.3389/fendo.2021.758896